mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma.
ASCO isn’t just a show for top 10 pharmas and Phase 3 readouts; it’s also a conference where smaller biopharmas share encouraging early-stage results, especially those that point to a new p
The first patient has received a personalised colorectal cancer vaccine, produced by BioNTech, as part of NHS England and Genomics England’s Cancer Vaccine Launch Pad (CVL
The first patient has been treated in a phase 1/2 clinical trial of an experimental Moderna vaccine designed to generate antibodies against PD-L1 and IDO1 – two targets th
MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non